Westlake Therapeutics is Drug Discovery in China that focus on Blood Cells business. Founded in 2019. They cover business area such as developer, cell therapy, disease, cellular medicine, engineer Red Blood Cells (RBC) therapeutic platform technology, a wide spectrum, cancer, genetic engineering, hematopoietic stem, progenitor cell, peripheral blood, bone marrow, cord blood, patient, well treatment.
2019
( 5 years old in 2024 )
Blood Cells
-
Room 202, Building 1
No.1, Yunmeng Road, Zhuantang Street, Xihu District
Hangzhou, Zhejiang
China
Private
developercell therapydiseasecellular medicineengineer Red Blood Cells (RBC) therapeutic platform technologya wide spectrumcancergenetic engineeringhematopoietic stemprogenitor cellperipheral bloodbone marrowcord bloodpatientwell treatment
* We use standard office opening hours in near Westlake Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Westlake Therapeutics is Drug Discovery business from China that founded in 2019 (5 years old in 2024), Westlake Therapeutics business is focusing on Blood Cells.
Westlake Therapeutics headquarter office and corporate office address is located in Room 202, Building 1 No.1, Yunmeng Road, Zhuantang Street, Xihu District Hangzhou, Zhejiang China.
Westlake Therapeutics was founded in China.
In 2024, Westlake Therapeutics is currently focus on Blood Cells sector.
Above is snippet of Google Trends for "Blood Cells" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Westlake Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
